SCHEMBL105389

SCHEMBL105389

CC(C)CC(C)(C)CN(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12039741 0.79
SCHEMBL13957849 0.79
SCHEMBL15865603 0.78
SCHEMBL19867554 0.77
SCHEMBL23084104 0.76 MEN1 (0.31)
SCHEMBL227850 0.75 CYP3A4 (0.34)
SCHEMBL13249198 0.75 TSHR (0.31)
SCHEMBL22432703 0.74
SCHEMBL3334025 0.74
SCHEMBL13821565 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230323027-A1 POLYMERISATION PROCESS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2023-10-12 US disclosed
WO-2023141866-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 WO disclosed
WO-2019238816-A1 BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 UNIVERSITY OF DUNDEE (GB) 2019-12-19 WO disclosed
WO-2019238886-A1 BIFUNCTIONAL MOLECULES FOR TARGETING USP14 UNIVERSITY OF DUNDEE (GB) 2019-12-19 WO disclosed
WO-2019190266-A1 PSMA-TARGETED RADIOPHARMACEUTICAL FOR DIAGNOSING AND TREATING PROSTATE CANCER (주)퓨쳐켐 2019-10-03 WO disclosed
EP-3274420-B1 CAPSULE SUITABLE FOR NON-INVASIVE SIMULTANEOUS OXYGEN CONTENT AND TEMPERATURE SENSING IN A LIVING OBJECT MAX PLANCK GESELLSCHAFT (DE) 2019-01-30 EP disclosed
EP-2595987-B1 NEW AMINOPYRAZOLOQUINAZOLINES BOEHRINGER INGELHEIM INT (DE) 2018-04-18 EP disclosed
US-9895443-B2 Multi-tailed lipids and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2018-02-20 US disclosed
EP-3067345-A1 ZWITTERION-CONTAINING ACRIDINIUM COMPOUNDS Siemens Healthcare Diagnostics Inc. (US) 2016-09-14 EP disclosed
US-20160158363-A1 MULTI-TAILED LIPIDS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2016-06-09 US disclosed
US-20120059162-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION ONCOTHERAPY SCIENCE, INC. (JP) 2012-03-08 US disclosed
EP-1603917-B1 IMMUNOMODULATING HETEROCYCLIC COMPOUNDS MEDIGENE LTD (GB) 2010-11-24 EP disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
CN-101657170-A Injectable cyanoacrylate-functionalized polyisobutylene UNIV AKRON US 2010-02-24 CN disclosed
US-20090298811-A1 BENZIMIDAZOLONE DERIVATIVES PFIZER INC 2009-12-03 US disclosed
EP-1730140-B1 OPIOID RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-06-25 EP disclosed
WO-2008032164-A2 BENZIMIDAZOLONE DERIVATIVES PFIZER PRODUCTS INC. (US) 2008-03-20 WO disclosed
US-20070225285-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-09-27 US disclosed
US-20070219206-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-09-20 US disclosed
US-20070219206-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-09-20 US disclosed